The clinical efficacy and tolerance of cefpiramide were studied in 34 patients at the age of 15 to 79 years with infectious destructive lesions in the lungs. The clinical efficacy amounted to 88.2 per cent. Out of 39 strains of grampositive and gramnegative aerobes and anaerobes 85 per cent were sensitive to cefpiramide. The bacteriological efficacy of cefpiramide amounted to 71.4 per cent. In 11.7 per cent of the patients involved in the trial there were recorded adverse reactions to cefpiramide. The results of the study made it possible to recommend the drug for the treatment of patients with severe and complicated infectious destructive lesions in the lungs.